Drug Trial Radar · NCT04752696
Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
41
Actual
Start
May 25, 2021
Primary completion
Dec 24, 2024
Study completion Dec 24, 2024
Sponsor
- Lead sponsor
- Cardiff OncologyIndustry
- Sponsor type
- Industry
- First posted
- Feb 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of this trial is to assess the efficacy of onvansertib in combination with nanoliposomal irinotecan (nal-IRI), leucovorin, and fluorouracil (5-FU) for treatment of participants with histologically confirmed metastatic PDAC.
Conditions
- Pancreatic Ductal Adenocarcinoma
Interventions
OnvansertibDrug
Oral capsule
Nanoliposomal irinotecanDrug
Intravenous infusion
LeucovorinDrug
Intravenous infusion
FluorouracilDrug
Intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Time frame: Up to approximately 91 weeks
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic Phoenix
Phoenix, Arizona
Mayo Clinic Jacksonville
Jacksonville, Florida
University of Kansas Medical Center
Westwood, Kansas
Mayo Clinic Rochester
Rochester, Minnesota
University of Nebraska Medical Center
Omaha, Nebraska
Inova Schar Cancer Institute
Fairfax, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.